Latest Bio-Rad Laboratories (BIO) Headlines
Bio-Rad Reports Fourth-Quarter and Full-Year 2013 Financial Results
Marketwire - Thu Feb 27, 3:15PM CST
Bio-Rad Laboratories, Inc. (NYSE: BIO) (NYSE: BIO.B), a global manufacturer and distributor of life science research and clinical diagnostic products, announced financial results today for the fourth quarter and fiscal year ended December 31, 2013.
Arik Air Expands Into West African Countries
All Africa Global Media - Wed Feb 26, 6:41AM CST
Arik Air has extended two of its existing routes as the airline continues its expansion programme for the regional West African services.
IIROC Trade Resumption - RMX
CNW Group - Thu Feb 20, 7:17AM CST
Trading resumes in:
Can Investors Gain from the New Age in Medical Testing?
Bob Chandler, The Motley Fool - Motley Fool - Thu Feb 06, 5:30PM CST
We might be entering a new age in medical testing. Molecular-level diagnostics, or tests based on the role genes play in human diseases, looks to provide earlier detection and more effective treatments for the most deadly conditions. Can investors...
Bio-Rad to Report Fourth-Quarter and Full-Year 2013 Financial Results Thursday, February 27, 2014
Marketwire - Mon Jan 27, 6:44PM CST
Bio-Rad Laboratories, Inc. (NYSE: BIO) and (NYSE: BIO.B), a multinational manufacturer and distributor of life science research and clinical diagnostic products, will report financial results for the fourth quarter and full year 2013 on Thursday, February 27, 2014, after the close of the market. The company will discuss these results in a conference call scheduled for 2 PM Pacific Time (5 PM Eastern Time) that day.
4 Stocks Rising on Unusual Volume
at The Street - Thu Jan 23, 6:00AM CST
Often when above-average volume moves into an equity, it precedes a large spike in volatility.
NYSE stocks posting largest volume increases
AP - Wed Jan 22, 5:03PM CST
NEW YORK (AP) — A look at the 10 biggest volume gainers on New York Stock Exchange at the close of trading:
Zacks #5 Rank Additions for Friday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Jan 03, 8:30AM CST
Here are 5 stocks added to the Zacks #5 Rank ("strong sell") List for Friday
Zacks #5 Rank Additions for Tuesday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Dec 31, 8:30AM CST
Here are 5 stocks added to the Zacks #5 Rank ("strong sell") List for Tuesday
New Products, Price Movements, and Leadership Appointments - Research Report on Waters, Cognex, Fluidigm, Cepheid, and Bio-Rad
PR Newswire - Mon Dec 23, 7:00AM CST
Today, Analysts' Corner announced new research reports highlighting Waters Corp. (NYSE: WAT), Cognex Corporation (NASDAQ: CGNX), Fluidigm Corporation (NASDAQ: FLDM), Cepheid (NASDAQ: CPHD), and Bio-Rad Laboratories, Inc. (NYSE: BIO). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
CareFusion Unveils New Technologies - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Dec 20, 12:50PM CST
CareFusion unveiled a number of technologies that will lead to better medication management with improved safety, efficiency and cost of intravenous (IV) medications.
athenahealth Collaborates with Merge - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Dec 19, 3:15PM CST
ATHN will use MRGE's iConnect Network in its cloud-based platform that will help its clients have real time access to view exam results, diagnostic images and other critical information within the athenaClinicals EHR workflow
Cerner Approves New Share Repurchase - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Dec 18, 1:30PM CST
Under the previous share repurchase program, authorized in December 2012, CERN repurchased 3.6 million shares for $170.0 million.
athenahealth Guides Higher Revs, Lower EPS - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Dec 16, 3:45PM CST
Following the announcement, athenahealth's shares slipped 3.2% to $126.60
St. Jude Authorizes Share Repurchase - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Dec 16, 12:40PM CST
Since 2010, St. Jude Medical has repurchased shares worth $3.0 billion.
Bio-Rad Announces the Appointment of New Board Member
Marketwire - Tue Dec 10, 3:15PM CST
Bio-Rad Laboratories, Inc. (NYSE: BIO) and (NYSE: BIO.B), a multinational manufacturer and distributor of life science research and clinical diagnostics products, announced today that Robert M. Malchione has been appointed to its Board of Directors effective January 1, 2014. Mr. Malchione will stand for election to the Board along with Bio-Rad's other directors at the Company's Annual Meeting on April 22, 2014.
Baxter, Cell Therapeutics to Jointly Develop Pacritinib - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 19, 1:00PM CST
According to the agreement, Baxter will provide an upfront payment of $60 million, including a $30 million equity investment in CTIC
Bio-Rad Reports Fourth-Quarter and Full-Year 2013 Financial Results
Marketwire - Thu Feb 27, 3:15PM CST
Bio-Rad Laboratories, Inc. (NYSE: BIO) (NYSE: BIO.B), a global manufacturer and distributor of life science research and clinical diagnostic products, announced financial results today for the fourth quarter and fiscal year ended December 31, 2013.
Arik Air Expands Into West African Countries
All Africa Global Media - Wed Feb 26, 6:41AM CST
Arik Air has extended two of its existing routes as the airline continues its expansion programme for the regional West African services.
IIROC Trade Resumption - RMX
CNW Group - Thu Feb 20, 7:17AM CST
Trading resumes in:
Can Investors Gain from the New Age in Medical Testing?
Bob Chandler, The Motley Fool - Motley Fool - Thu Feb 06, 5:30PM CST
We might be entering a new age in medical testing. Molecular-level diagnostics, or tests based on the role genes play in human diseases, looks to provide earlier detection and more effective treatments for the most deadly conditions. Can investors...
Bio-Rad to Report Fourth-Quarter and Full-Year 2013 Financial Results Thursday, February 27, 2014
Marketwire - Mon Jan 27, 6:44PM CST
Bio-Rad Laboratories, Inc. (NYSE: BIO) and (NYSE: BIO.B), a multinational manufacturer and distributor of life science research and clinical diagnostic products, will report financial results for the fourth quarter and full year 2013 on Thursday, February 27, 2014, after the close of the market. The company will discuss these results in a conference call scheduled for 2 PM Pacific Time (5 PM Eastern Time) that day.
4 Stocks Rising on Unusual Volume
at The Street - Thu Jan 23, 6:00AM CST
Often when above-average volume moves into an equity, it precedes a large spike in volatility.
NYSE stocks posting largest volume increases
AP - Wed Jan 22, 5:03PM CST
NEW YORK (AP) — A look at the 10 biggest volume gainers on New York Stock Exchange at the close of trading:
Zacks #5 Rank Additions for Friday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Jan 03, 8:30AM CST
Here are 5 stocks added to the Zacks #5 Rank ("strong sell") List for Friday
Zacks #5 Rank Additions for Tuesday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Dec 31, 8:30AM CST
Here are 5 stocks added to the Zacks #5 Rank ("strong sell") List for Tuesday
New Products, Price Movements, and Leadership Appointments - Research Report on Waters, Cognex, Fluidigm, Cepheid, and Bio-Rad
PR Newswire - Mon Dec 23, 7:00AM CST
Today, Analysts' Corner announced new research reports highlighting Waters Corp. (NYSE: WAT), Cognex Corporation (NASDAQ: CGNX), Fluidigm Corporation (NASDAQ: FLDM), Cepheid (NASDAQ: CPHD), and Bio-Rad Laboratories, Inc. (NYSE: BIO). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
CareFusion Unveils New Technologies - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Dec 20, 12:50PM CST
CareFusion unveiled a number of technologies that will lead to better medication management with improved safety, efficiency and cost of intravenous (IV) medications.
athenahealth Collaborates with Merge - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Dec 19, 3:15PM CST
ATHN will use MRGE's iConnect Network in its cloud-based platform that will help its clients have real time access to view exam results, diagnostic images and other critical information within the athenaClinicals EHR workflow
Cerner Approves New Share Repurchase - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Dec 18, 1:30PM CST
Under the previous share repurchase program, authorized in December 2012, CERN repurchased 3.6 million shares for $170.0 million.
athenahealth Guides Higher Revs, Lower EPS - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Dec 16, 3:45PM CST
Following the announcement, athenahealth's shares slipped 3.2% to $126.60
St. Jude Authorizes Share Repurchase - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Dec 16, 12:40PM CST
Since 2010, St. Jude Medical has repurchased shares worth $3.0 billion.
Bio-Rad Announces the Appointment of New Board Member
Marketwire - Tue Dec 10, 3:15PM CST
Bio-Rad Laboratories, Inc. (NYSE: BIO) and (NYSE: BIO.B), a multinational manufacturer and distributor of life science research and clinical diagnostics products, announced today that Robert M. Malchione has been appointed to its Board of Directors effective January 1, 2014. Mr. Malchione will stand for election to the Board along with Bio-Rad's other directors at the Company's Annual Meeting on April 22, 2014.
Baxter, Cell Therapeutics to Jointly Develop Pacritinib - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 19, 1:00PM CST
According to the agreement, Baxter will provide an upfront payment of $60 million, including a $30 million equity investment in CTIC
